For Immediate Release
Discovery Could Lead to More Effective Treatments
Dateline: Chicago, IL, March 22, 2016:
In the current issue of the peer-reviewed medical journal, Phytotherapy Research™, investigators have shown that a new, novel, naturally-based formula, CXJ15a, has outperformed benchmark drug (finasteride) in reducing a number of gene expression markers linked to common pattern hair loss and benign prostatic hyperplasia (BPH).
Link To New Hair Growth Formula Study
Comparison to Finasteride
Finasteride, marketed in 1 mg dosage under the trade name Propecia™ and in 5 mg dosage under the trade name Proscar™ constitutes the most widely prescribed oral drug for both pattern hair loss and BPH, respectively. While shown to be clinically effective, finasteride has also been associated with serious negative side effects, and the medication is not available for use by females.
The new study tested a proprietary, botanically-derived composition, CXJ15a, developed by Advanced Restoration Technologies (ART) and found it superior to finasteride in reducing a number of gene expression markers linked to both disorders. “The idea of developing safer, more effective treatments constitutes an important goal, particularly in hair loss where a dearth of viable options has long been the case” said the study coauthor, Glenn Mouser.
Corresponding author Geno Marcovici concurs with Mouser, noting that “our company’s mission has been to create safe and increasingly effective treatments against hair loss, via the highest level of scientifically valid testing methodology possible, yet free from the negative side effects commonly associated with the drug-based alternatives.”
Novel Dual-Mechanism Of Action
Because chronic inflammation is considered a contributing factor in the progression of pattern hair loss and also BPH, the study investigators sought to measure the test material’s ability to block key markers of pathologic inflammation by using well-validated molecular assays representative of hair follicles and prostate tissue. Specifically, the research team found that the test compound not only outperformed finasteride in all parameters measured, but strongly suppressed gene expression of several inflammatory chemokines linked to both disorders.
In addition to anti-inflammatory substances, CXJ15a was formulated with a subset of botanically derived, highly potent 5 alpha-reductase (5AR) inhibitors. 5AR catalyzes the conversion of testosterone (T) to its more pathological metabolite dihydrotestosterone (DHT). DHT is a well-known trigger of pattern hair loss. Thus, by combining targeted anti-inflammatory agents with potent 5AR inhibitors the test composition has been designed to offer enhanced clinical efficacy over conventional hair loss monotherapy.
Corresponding author Geno Marcovici, Ph.D. has been active in the hair loss field for more than two decades. Explaining the importance of validating ART’s proprietary formulations Marcovici notes that “[a]side from ART’s own HairGenesis® brand of products, the naturally-derived hair treatments commercially available typically offer little or no objective evidence that they work. On the other hand, the drug-based treatments that do work come with potentially serious negative side effects. This tends to render HairGenesis® a unique proposition in the category. ” Marcovici adds “what we learn in the lab and test in the clinic we are then able to incorporate into our HairGenesis® product line – ultimately to the benefit of our longtime users”.
About Wiley Publishing & Phytotherapy Research™ Journal
is the international scientific, medical, and scholarly publishing division of John Wiley & Sons, with strengths in every major academic and professional research field and is in partnership with many of the world's leading medical institutions & societies. Significantly, Wiley has promulgated the discoveries of more than 460 Nobel Prize winning investigators, including the distinguished work of eight 2015 Nobel Laureates. This prestigious accolade exemplifies Wiley's commitment to disseminating the latest world-class research content for the benefit of the academic and scholarly communities.
With an impact factor of 2.66, Phytotherapy Research™ is one of Wiley’s most well-respected, monthly peer-reviewed scientific journals. Key areas of interest in the Journal include pharmacology, toxicology, and the clinical applications of novel, naturally derived compounds in medicine, from basic science studies & case histories to full clinical trials. Papers concerned with the effects of standardized plant extracts, including their application in novel commercial products, are particularly relevant, as are mechanistic studies on isolated natural substances.
For more information contact:
Geno Marcovici, Ph.D., DABAAHP
# # #